Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson… Read more
Prothena Corporation plc (PRTA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.138x
Based on the latest financial reports, Prothena Corporation plc (PRTA) has a cash flow conversion efficiency ratio of -0.138x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-40.56 Million) by net assets ($294.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Prothena Corporation plc - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Prothena Corporation plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Prothena Corporation plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Prothena Corporation plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Adaptive Plasma Technology Corp
KQ:089970
|
0.056x |
|
Longmaster Information Tech
SHE:300288
|
-0.007x |
|
Grindr Inc
NYSE:GRND
|
0.781x |
|
AB Dynamics plc
PINK:ABDDF
|
0.024x |
|
ZKTECO Co. Ltd. A
SHE:301330
|
N/A |
|
Shenzhen Soling Industrial Co Ltd
SHE:002766
|
-0.008x |
|
Cowealth Medical China Co.Ltd.
SHG:603122
|
N/A |
|
361 Degrees International Limited
PINK:TSIOF
|
0.050x |
Annual Cash Flow Conversion Efficiency for Prothena Corporation plc (2010–2024)
The table below shows the annual cash flow conversion efficiency of Prothena Corporation plc from 2010 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $486.93 Million | $-150.05 Million | -0.308x | -29.19% |
| 2023-12-31 | $561.37 Million | $-133.91 Million | -0.239x | -36.35% |
| 2022-12-31 | $622.04 Million | $-108.82 Million | -0.175x | -188.04% |
| 2021-12-31 | $466.04 Million | $92.61 Million | 0.199x | +145.50% |
| 2020-12-31 | $184.01 Million | $-80.36 Million | -0.437x | -125.03% |
| 2019-12-31 | $272.92 Million | $-52.97 Million | -0.194x | -121.70% |
| 2018-12-31 | $323.00 Million | $-28.28 Million | -0.088x | +72.83% |
| 2017-12-31 | $407.19 Million | $-131.18 Million | -0.322x | -0.39% |
| 2016-12-31 | $365.40 Million | $-117.27 Million | -0.321x | -85.33% |
| 2015-12-31 | $360.67 Million | $-62.45 Million | -0.173x | -7249.70% |
| 2014-12-31 | $289.89 Million | $-683.00K | -0.002x | +98.73% |
| 2013-12-31 | $173.27 Million | $-32.10 Million | -0.185x | +44.31% |
| 2012-12-31 | $126.48 Million | $-42.07 Million | -0.333x | -110.87% |
| 2011-12-31 | $-6.44 Million | $-19.70 Million | 3.060x | +103.37% |
| 2010-12-31 | $100.00K | $-9.08 Million | -90.830x | -- |